Pacer Advisors
BPMC

Pacer Advisors’s Blueprint Medicines BPMC Stock Holding History

Pacer Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-540
Closed -$58.2K – 2582
2024
Q2 		$58.2K Buy
540
+77
+17% +$7.71K ﹤0.01% 3039
2024
Q1 		$43.9K Buy
+463
New +$39.7K ﹤0.01% 3220
2021
Q2 		– Sell
-724
Closed -$70K – 1430
2021
Q1 		$70K Sell
724
-428
-37% -$42.7K ﹤0.01% 1368
2020
Q4 		$129K Sell
1,152
-350
-23% -$36.9K ﹤0.01% 1318
2020
Q3 		$139K Buy
+1,502
New +$116K ﹤0.01% 1219
2018
Q4 		– Sell
-3,661
Closed -$286K – 598
2018
Q3 		$286K Buy
+3,661
New +$254K 0.01% 960
2018
Q1 		– Sell
-1,000
Closed -$75K – 1049
2017
Q4 		$75K Buy
+1,000
New +$70.4K 0.01% 985

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pacer Advisors's BPMC Position: Q3 2024 in Review

Pacer Advisors sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 540 shares — an estimated $58.2K sold.

Pacer Advisors first reported a position in BPMC in Q4 2017 and held it in 7 quarters. The position peaked at $286K in Q3 2018. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Pacer Advisors reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 540 Blueprint Medicines shares in Q3 2024, an estimated $58.2K.
  • Pacer Advisors first reported a position in Blueprint Medicines in Q4 2017 and held it in 7 quarters.
  • Pacer Advisors's Blueprint Medicines position peaked at $286K in Q3 2018.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.